NovaSight

Company Overview

Snapshot

Founded in February 2016 by Danny Oz, NovaSight operates with 11–50 employees. The company has raised a total of $38.88 million across 6 funding rounds from 10 investors.

Business overview

NovaSight is a medical device company focused on preventing vision impairments in pediatric patients through eye-tracking technology. The company develops novel diagnostic, therapeutic, and preventive solutions tailored for children, addressing vision treatment, diagnostics, and monitoring of visual health conditions. Its core product, CureSight, is an FDA-cleared and CE-marked amblyopia treatment system that replaces traditional eye patching by blurring the dominant eye's vision while the patient watches streamed content. NovaSight also offers EyeSwiftPRO for automated vision testing and is developing TrackSight, a SaaS solution for myopia prevention and visual health monitoring for both children and adults. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Healthcare, utilizing AI, deep learning, and computer vision technologies.

Strategic signal

In September 2024, NovaSight's CureSight system demonstrated superior visual acuity gains compared to traditional patching for amblyopia patients. This finding, published in a peer-reviewed journal, validates the efficacy of their digital therapeutic approach and signals a potential shift in standard pediatric vision care, offering a more engaging and effective treatment option for investors and healthcare providers.

Company Intelligence Q&A

What is NovaSight's flagship product for amblyopia treatment?

NovaSight's flagship product is CureSight, an FDA-cleared and CE-marked amblyopia treatment system. It replaces traditional eye patching by blurring the dominant eye's vision while the patient watches streamed content, stimulating the amblyopic eye to improve acuity and develop stereoacuity.

When did NovaSight receive FDA clearance for its CureSight digital therapy?

NovaSight announced FDA 510(K) clearance for its CureSight digital therapy for amblyopia in October 2022.

What was a significant recent recognition for NovaSight's CureSight product?

In May 2023, NovaSight's CureSight won the 2023 MedTech Breakthrough Award, recognizing its innovative approach to pediatric vision care.

What was a key finding from a recent study on CureSight?

In March 2024, NovaSight reported long-term vision gains in a CureSight study, with the pivotal study of 1-year follow-up outcomes being published in the same month.